Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 2.30
LXRX's Cash-to-Debt is ranked lower than
69% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. LXRX: 2.30 )
Ranked among companies with meaningful Cash-to-Debt only.
LXRX' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.31  Med: 4.65 Max: No Debt
Current: 2.3
Equity-to-Asset 0.29
LXRX's Equity-to-Asset is ranked lower than
83% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. LXRX: 0.29 )
Ranked among companies with meaningful Equity-to-Asset only.
LXRX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.29  Med: 0.62 Max: 0.96
Current: 0.29
0.29
0.96
Debt-to-Equity 0.95
LXRX's Debt-to-Equity is ranked lower than
84% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. LXRX: 0.95 )
Ranked among companies with meaningful Debt-to-Equity only.
LXRX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01  Med: 0.2 Max: 0.95
Current: 0.95
0.01
0.95
Debt-to-EBITDA -0.73
LXRX's Debt-to-EBITDA is ranked lower than
99.99% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. LXRX: -0.73 )
Ranked among companies with meaningful Debt-to-EBITDA only.
LXRX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.12  Med: -0.33 Max: 37.2
Current: -0.73
-1.12
37.2
Altman Z-Score: -3.01
Beneish M-Score: 5.37
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -175.88
LXRX's Operating Margin % is ranked lower than
55% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. LXRX: -175.88 )
Ranked among companies with meaningful Operating Margin % only.
LXRX' s Operating Margin % Range Over the Past 10 Years
Min: -9955.46  Med: -639.94 Max: 1.13
Current: -175.88
-9955.46
1.13
Net Margin % -170.63
LXRX's Net Margin % is ranked lower than
56% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. LXRX: -170.63 )
Ranked among companies with meaningful Net Margin % only.
LXRX' s Net Margin % Range Over the Past 10 Years
Min: -10120.39  Med: -606.25 Max: -3.6
Current: -170.63
-10120.39
-3.6
ROE % -86.40
LXRX's ROE % is ranked lower than
72% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. LXRX: -86.40 )
Ranked among companies with meaningful ROE % only.
LXRX' s ROE % Range Over the Past 10 Years
Min: -86.4  Med: -43.42 Max: -1.64
Current: -86.4
-86.4
-1.64
ROA % -29.95
LXRX's ROA % is ranked higher than
52% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. LXRX: -29.95 )
Ranked among companies with meaningful ROA % only.
LXRX' s ROA % Range Over the Past 10 Years
Min: -32.59  Med: -27.19 Max: -0.83
Current: -29.95
-32.59
-0.83
ROC (Joel Greenblatt) % -723.19
LXRX's ROC (Joel Greenblatt) % is ranked lower than
57% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. LXRX: -723.19 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
LXRX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -723.19  Med: -202.19 Max: 15.03
Current: -723.19
-723.19
15.03
3-Year Revenue Growth Rate 199.00
LXRX's 3-Year Revenue Growth Rate is ranked higher than
98% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. LXRX: 199.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
LXRX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -71.6  Med: 13 Max: 328.1
Current: 199
-71.6
328.1
3-Year EBITDA Growth Rate -1.90
LXRX's 3-Year EBITDA Growth Rate is ranked lower than
56% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. LXRX: -1.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
LXRX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -28.5  Med: -8.7 Max: 22.5
Current: -1.9
-28.5
22.5
3-Year EPS without NRI Growth Rate -1.40
LXRX's 3-Year EPS without NRI Growth Rate is ranked higher than
50% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. LXRX: -1.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
LXRX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -68.6  Med: -11.1 Max: 29.1
Current: -1.4
-68.6
29.1
GuruFocus has detected 4 Warning Signs with Lexicon Pharmaceuticals Inc LXRX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» LXRX's 30-Y Financials

Financials (Next Earnings Date: 2017-11-01)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

LXRX Guru Trades in Q3 2016

Paul Tudor Jones 41,850 sh (+238.84%)
Mario Gabelli 14,600 sh (-9.32%)
Joel Greenblatt 47,635 sh (-83.86%)
» More
Q4 2016

LXRX Guru Trades in Q4 2016

Mario Gabelli 14,600 sh (unchged)
Paul Tudor Jones 30,574 sh (-26.94%)
Joel Greenblatt 27,102 sh (-43.10%)
» More
Q1 2017

LXRX Guru Trades in Q1 2017

Steven Cohen 382,500 sh (New)
Jim Simons 261,505 sh (New)
Mario Gabelli 14,600 sh (unchged)
Joel Greenblatt Sold Out
Paul Tudor Jones 25,827 sh (-15.53%)
» More
Q2 2017

LXRX Guru Trades in Q2 2017

Jim Simons 384,097 sh (+46.88%)
Mario Gabelli 14,600 sh (unchged)
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NAS:LXRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-03-31 Sold Out $13.68 - $16.73 $ 11.19-25%0
Joel Greenblatt 2016-12-31 Reduce -43.10%$13.83 - $19.3 $ 11.19-30%27,102
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:SZSE:000403, NAS:AIMT, SHSE:603718, XSWX:SFZN, NAS:DVAX, NYSE:CO, NAS:GBT, SZSE:002022, TSE:4565, SZSE:300255, NYSE:BHVN, OCSE:BAVA, NAS:ESPR, XTER:BIO3, XKRX:005250, NAS:ZLAB, NAS:SGMO, NAS:ASND, NAS:ICPT, SZSE:000518 » details
Traded in other countries:LX31.Germany,
Headquarter Location:USA
Lexicon Pharmaceuticals Inc operates as a biopharmaceutical company engaged in discovery and development of breakthrough treatments for human disease. The company mainly designs and develops drugs for therapeutic areas.

Lexicon Pharmaceuticals is a biopharmaceutical company that uses mouse genetics to discover the function of genes and find promising drug targets. Lexicon then designs and develops drugs for these targets, which cover a broad spectrum of therapeutic areas. Following a restructuring in January 2014, Lexicon is focusing efforts on two drugs: sotagliflozin (LX4211) in diabetes, which is partnered with Sanofi, and Xermelo (telotristat etiprate) in carcinoid syndrome, which is partnered with Ipsen outside the U.S.

Top Ranked Articles about Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Initiates Patient Dosing In A Phase 1 Study Of LX9211
Weekly CEO Buys Highlights Insiders invest in OPKO Health, Cleveland-Cliffs, Lexicon Pharmaceuticals, Delek Logistics Partners and Radius Health
According to GuruFocus Insider Data, these are the largest CEO buys during the past week.  Read more...
European Commission Approves XERMELO® (Telotristat Ethyl) For The Treatment Of Carcinoid Syndrome Diarrhea In Combination With Somatostatin Analog Therapy
Lexicon Pharmaceuticals To Present At The 2017 Cantor Fitzgerald Global Healthcare Conference
New England Journal Of Medicine Publishes Data From Phase 3 inTandem3 Study Of Sotagliflozin In Patients With Type 1 Diabetes
Lexicon Pharmaceuticals To Present At The Bank Of America Merrill Lynch 2017 Global Healthcare Conference
Lexicon Pharmaceuticals Announces Four Data Presentations At The European Society Of Medical Oncology 2017 Congress
Lexicon Pharmaceuticals to Present New Clinical Data at the European Association for the Study of Diabetes 53rd Annual Meeting
Lexicon Pharmaceuticals Reports Additional Positive Data From Pivotal Phase 3 inTandem2 Study Of Sotagliflozin
Lexicon Pharmaceuticals To Present At 2017 Wedbush PacGrow Healthcare Conference

Ratios

vs
industry
vs
history
PB Ratio 11.11
LXRX's PB Ratio is ranked lower than
85% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. LXRX: 11.11 )
Ranked among companies with meaningful PB Ratio only.
LXRX' s PB Ratio Range Over the Past 10 Years
Min: 0.66  Med: 3.29 Max: 17.76
Current: 11.11
0.66
17.76
PS Ratio 14.39
LXRX's PS Ratio is ranked lower than
57% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. LXRX: 14.39 )
Ranked among companies with meaningful PS Ratio only.
LXRX' s PS Ratio Range Over the Past 10 Years
Min: 3.05  Med: 25.37 Max: 1440
Current: 14.39
3.05
1440
EV-to-EBIT -7.47
LXRX's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. LXRX: -7.47 )
Ranked among companies with meaningful EV-to-EBIT only.
LXRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -229  Med: -4.1 Max: 484.7
Current: -7.47
-229
484.7
EV-to-EBITDA -7.60
LXRX's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. LXRX: -7.60 )
Ranked among companies with meaningful EV-to-EBITDA only.
LXRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -281.1  Med: -4.4 Max: 357.4
Current: -7.6
-281.1
357.4
EV-to-Revenue 12.94
LXRX's EV-to-Revenue is ranked lower than
53% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. LXRX: 12.94 )
Ranked among companies with meaningful EV-to-Revenue only.
LXRX' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.9  Med: 19.7 Max: 1310.4
Current: 12.94
0.9
1310.4
Current Ratio 1.86
LXRX's Current Ratio is ranked lower than
76% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. LXRX: 1.86 )
Ranked among companies with meaningful Current Ratio only.
LXRX' s Current Ratio Range Over the Past 10 Years
Min: 0.95  Med: 6.25 Max: 31.11
Current: 1.86
0.95
31.11
Quick Ratio 1.85
LXRX's Quick Ratio is ranked lower than
72% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. LXRX: 1.85 )
Ranked among companies with meaningful Quick Ratio only.
LXRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.95  Med: 6.25 Max: 31.11
Current: 1.85
0.95
31.11
Days Inventory 100.30
LXRX's Days Inventory is ranked higher than
64% of the 473 Companies
in the Global Biotechnology industry.

( Industry Median: 134.39 vs. LXRX: 100.30 )
Ranked among companies with meaningful Days Inventory only.
LXRX' s Days Inventory Range Over the Past 10 Years
Min: 0  Med: 0 Max: 100.3
Current: 100.3
0
100.3
Days Sales Outstanding 22.57
LXRX's Days Sales Outstanding is ranked higher than
84% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. LXRX: 22.57 )
Ranked among companies with meaningful Days Sales Outstanding only.
LXRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.56  Med: 30.31 Max: 461.86
Current: 22.57
2.56
461.86
Days Payable 21.00
LXRX's Days Payable is ranked lower than
77% of the 434 Companies
in the Global Biotechnology industry.

( Industry Median: 57.10 vs. LXRX: 21.00 )
Ranked among companies with meaningful Days Payable only.
LXRX' s Days Payable Range Over the Past 10 Years
Min: 0  Med: 0 Max: 21
Current: 21
0
21

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -12.40
LXRX's 3-Year Average Share Buyback Ratio is ranked higher than
53% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. LXRX: -12.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
LXRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -52  Med: -15 Max: -6.9
Current: -12.4
-52
-6.9

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 124.33
LXRX's Price-to-Tangible-Book is ranked lower than
99% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. LXRX: 124.33 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
LXRX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.89  Med: 4.4 Max: 193.53
Current: 124.33
0.89
193.53
Price-to-Median-PS-Value 0.57
LXRX's Price-to-Median-PS-Value is ranked higher than
73% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. LXRX: 0.57 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
LXRX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.11  Med: 0.6 Max: 46.28
Current: 0.57
0.11
46.28
Earnings Yield (Greenblatt) % -13.38
LXRX's Earnings Yield (Greenblatt) % is ranked lower than
59% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. LXRX: -13.38 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
LXRX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1305.1  Med: -15.7 Max: 52.6
Current: -13.38
-1305.1
52.6

More Statistics

Revenue (TTM) (Mil) $81.10
EPS (TTM) $ -1.32
Beta-0.08
Short Percentage of Float55.21%
52-Week Range $10.96 - 18.00
Shares Outstanding (Mil)105.58

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 81 122 306 648
EPS ($) -1.33 -0.98 0.83 3.04
EPS without NRI ($) -1.33 -0.98 0.83 3.04
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: ----
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}